Prelude Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Prelude Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,135	Closed	-$225K	–	1362
2025 Q2	$225K	Buy	+13,135	New	+$560K	0.02%	751
2024 Q4	–	Sell	-1,832	Closed	-$229K	–	1545
2024 Q3	$229K	Sell	1,832 -8,334	-82%	-$1.15M	0.01%	1003
2024 Q2	$1.61M	Buy	+10,166	New	+$1.31M	0.11%	228
2023 Q4	–	Sell	-10,483	Closed	-$1.27M	–	1325
2023 Q3	$1.27M	Buy	10,483 +3,475	+50%	+$393K	0.08%	266
2023 Q2	$803K	Buy	7,008 +3,507	+100%	+$452K	0.05%	341
2023 Q1	$483K	Buy	+3,501	New	+$454K	0.03%	474
2022 Q4	–	Sell	-4,239	Closed	-$469K	–	1595
2022 Q3	$469K	Sell	4,239 -297	-7%	-$29.9K	0.02%	682
2022 Q2	$340K	Buy	+4,536	New	+$334K	0.01%	996
2021 Q3	–	Sell	-4,621	Closed	-$359K	–	2011
2021 Q2	$359K	Buy	+4,621	New	+$350K	0.01%	1118
2021 Q1	–	Sell	-1,331	Closed	-$227K	–	1796
2020 Q4	$227K	Sell	1,331 -116	-8%	-$17.2K	0.01%	1048
2020 Q3	$203K	Sell	1,447 -7,862	-84%	-$1.19M	0.01%	690
2020 Q2	$1.49M	Buy	+9,309	New	+$1.27M	0.08%	220
2019 Q3	–	Sell	-1,152	Closed	-$136K	–	2022
2019 Q2	$175K	Buy	1,152 +312	+37%	+$37.9K	0.01%	775
2019 Q1	$100K	Sell	840 -129	-13%	-$16.6K	0.01%	932
2018 Q4	$106K	Sell	969 -6,598	-87%	-$825K	0.01%	911
2018 Q3	$1.22M	Buy	7,567 +988	+15%	+$135K	0.07%	324
2018 Q2	$870K	Sell	6,579 -14,870	-69%	-$1.4M	0.06%	370
2018 Q1	$1.59M	Sell	21,449 -14,612	-41%	-$974K	0.12%	171
2017 Q4	$2.01M	Sell	36,061 -48,165	-57%	-$2.55M	0.16%	130
2017 Q3	$3.82M	Sell	84,226 -3,827	-4%	-$153K	0.34%	57
2017 Q2	$2.97M	Buy	88,053 +45,577	+107%	+$1.48M	0.28%	74
2017 Q1	$1.26M	Buy	42,476 +38,752	+1,041%	+$1.2M	0.12%	201
2016 Q4	$102K	Buy	3,724 +1,624	+77%	+$65.2K	0.01%	819
2016 Q3	$129K	Buy	+2,100	New	+$63.5K	0.01%	731
2016 Q1	–	Sell	-1,000	Closed	-$39K	–	1502
2015 Q4	$39K	Buy	+1,000	New	+$32.4K	0.01%	1092
2015 Q1	–	Sell	-1,000	Closed	-$13.3K	–	2159
2014 Q4	$14K	Sell	1,000 -2,200	-69%	-$37.3K	﹤0.01%	1780
2014 Q3	$68K	Buy	3,200 +2,200	+220%	+$49.7K	0.01%	1273
2014 Q2	$30K	Sell	1,000 -5,800	-85%	-$183K	﹤0.01%	1645
2014 Q1	$163K	Buy	6,800 +5,105	+301%	+$130K	0.02%	804
2013 Q4	$35K	Sell	1,695 -9,800	-85%	-$291K	0.01%	1209
2013 Q3	$543K	Sell	11,495 -1,505	-12%	-$58K	0.09%	273
2013 Q2	$495K	Buy	+13,000	New	+$465K	0.11%	253

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prelude Capital Management's SRPT Position: Q3 2025 in Review

Prelude Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 13,135 shares — an estimated $225K sold.

Prelude Capital Management first reported a position in SRPT in Q2 2013 and held it in 32 quarters. The position peaked at $3.82M in Q3 2017. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Prelude Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 13,135 Sarepta Therapeutics shares in Q3 2025, an estimated $225K.
Prelude Capital Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 32 quarters.
Prelude Capital Management's Sarepta Therapeutics position peaked at $3.82M in Q3 2017.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.